Ovarian cancer

You have access
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Ovarian Cancer: Evaluation of Side Effects in a Single Institution Cohort
MICHAEL FRIEDRICH, WOLFGANG ZINN, LAURA KOLNSBERG, CLAYTON KRAFT and WALTHER KUHN

Anticancer Research March 2020, 40 (3) 1481-1486; DOI: https://doi.org/10.21873/anticanres.14092
You have access
Increased Immunosuppression Is Related to Increased Amounts of Ascites and Inferior Prognosis in Ovarian Cancer
AN COOSEMANS, THAIS BAERT, VICTORIA D'HEYGERE, ROXANNE WOUTERS, LARA DE LAET, ANAIS VAN HOYLANDT, GITTE THIRION, JOLIEN CEUSTERS, ANNOUSCHKA LAENEN, VINCENT VANDECAVEYE and IGNACE VERGOTE

Anticancer Research November 2019, 39 (11) 5953-5962; DOI: https://doi.org/10.21873/anticanres.13800
You have access
MLH1 Is a Prognostic Biomarker for Serous Ovarian Cancer Treated With Platinum- and Taxane-based Chemotherapy
NAOYUKI KAWASHIMA, HIROYUKI YOSHIDA, MAIKO MIWA and KEIICHI FUJIWARA

Anticancer Research October 2019, 39 (10) 5505-5513; DOI: https://doi.org/10.21873/anticanres.13743
You have access
Prevention of Anastomotic Leakage in Ovarian Cancer Debulking Surgery and Its Impact on Overall Survival
ARNE KOSCIELNY, ANNA KO, EVA K. EGGER, WALTER KUHN, JÖRG C. KALFF and MIGNON-DENISE KEYVER-PAIK

Anticancer Research September 2019, 39 (9) 5209-5218; DOI: https://doi.org/10.21873/anticanres.13718
You have access
Ovarian Cancer Treatment Stratification Using Ex Vivo Drug Sensitivity Testing
INES LOHSE, DIANA J. AZZAM, HASSAN AL-ALI, CLAUDE-HENRY VOLMAR, SHAUN P. BROTHERS, TAN A. INCE and CLAES WAHLESTEDT

Anticancer Research August 2019, 39 (8) 4023-4030; DOI: https://doi.org/10.21873/anticanres.13558
You have access
MMP-2 mRNA Expression in Ovarian Cancer Tissues Predicts Patients' Response to Platinum-Taxane Chemotherapy
WITOLD JELENIEWICZ, MAREK CYBULSKI, ANDRZEJ NOWAKOWSKI, AGNIESZKA STENZEL-BEMBENEK, MAŁGORZATA GUZ, BARBARA MARZEC-KOTARSKA, JAN KOTARSKI and ANDRZEJ STEPULAK

Anticancer Research April 2019, 39 (4) 1821-1827; DOI: https://doi.org/10.21873/anticanres.13289
You have access
ROBO1 Expression in Metastasizing Breast and Ovarian Cancer: SLIT2-induced Chemotaxis Requires Heparan Sulfates (Heparin)
GÜNTHER A. REZNICZEK, CHRISTINE GRUNWALD, ZIAD HILAL, JAN SCHEICH, GUIDO REIFENBERGER, ANDREA TANNAPFEL and CLEMENS B. TEMPFER

Anticancer Research March 2019, 39 (3) 1267-1273; DOI: https://doi.org/10.21873/anticanres.13237
You have access
Association of CD31 and p53 With Survival of Ovarian Cancer Patients
LENE RASK, CLAUS K. HØGDALL, SUSANNE K. KJAER, LISE CHRISTENSEN, ALLAN JENSEN, JAN BLAAKAER, IB JARLE CHRISTENSEN and ESTRID V.S. HØGDALL

Anticancer Research February 2019, 39 (2) 567-576; DOI: https://doi.org/10.21873/anticanres.13149
You have access
Comparison of Primary Tumor Size in Stage I and III Epithelial Ovarian Cancer
EDGAR PETRU, CAROLA HUBER, EVA SAMPL and JOSEF HAAS

Anticancer Research November 2018, 38 (11) 6507-6511; DOI: https://doi.org/10.21873/anticanres.13015
You have access
Increased Soluble PD-L1 Levels in the Plasma of Patients with Epithelial Ovarian Cancer Correlate with Plasma Levels of miR34a and miR200
MICHAEL I. KOUKOURAKIS, EMMANUEL KONTOMANOLIS, MARIA SOTIROPOULOU, ACHILLEAS MITRAKAS, EVANGELIA DAFA, STAMATIA POULILIOU, EFTHIMIOS SIVRIDIS and ALEXANDRA GIATROMANOLAKI

Anticancer Research October 2018, 38 (10) 5739-5745; DOI: https://doi.org/10.21873/anticanres.12912

Main menu

User menu

Search

Ovarian cancer

Pages